drugset / Trial / NCT02559154
Modified Bortezomib-based Combination Therapy for Multiple Myeloma
Phase 4
Unknown
80 enrolled
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Non-randomizedParallel-groupOpen-labelTreatment
Summary
To investigate the efficacy of a modified bortezomib based combination therapy for patients with multiple myeloma.
Timeline
- Start
- 2010-07
- Primary completion
- 2018-10
- Completion
- 2018-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bortezomib | Small molecule | 1.3 mg/m2 | Intravenous |
| Subject | Bortezomib | Small molecule | 1.6 mg/m2 | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | — | — |
| Background | Dexamethasone | Small molecule | — | — |
| Background | Doxorubicin | Other / unclassified | — | — |
| Background | Mitoxsnteone | Unknown | — | — |
| Background | Thalidomide | Other / unclassified | — | — |